中危患者经导管与外科主动脉瓣置换术后神经系统并发症比较
基于SURTAVI随机试验的改良意向治疗人群(平均年龄79.8±6.2岁,N=1,660),分析中危重度症状性主动脉狭窄患者TAVR与SAVR术后神经事件。结果显示SAVR早期卒中(5.4% vs 3.3%,p=0.031)和术后脑病(7.8% vs 1.6%,p<0.001)发生率高于TAVR;12个月时卒中率无差异(6.9% vs 5.2%,p=0.136)。早期卒中后SAVR患者30天生活质量低于TAVR,6和12个月时相似。
要点
- SAVR术后30天卒中和脑病发生率显著高于TAVR。
- 12个月时TAVR与SAVR的卒中率无显著差异。
- 早期卒中后TAVR患者30天生活质量优于SAVR。
核心结论
- TAVR早期卒中率低于SAVR,早期卒中后TAVR生活质量改善更早;12个月时卒中率和生活质量无差异。
研究设计与样本
- SURTAVI随机试验的改良意向治疗分析,中危重度症状性主动脉狭窄患者1:1随机至TAVR或SAVR,平均年龄79.8±6.2岁,N=1,660。
主要发现
- 30天卒中率SAVR 5.4% vs TAVR 3.3%(p=0.031),术后脑病SAVR 7.8% vs TAVR 1.6%(p<0.001)。
- 12个月卒中率SAVR 6.9% vs TAVR 5.2%(p=0.136)。
- 早期卒中和早期脑病均导致两组12个月死亡率升高。
- 早期卒中后30天生活质量SAVR显著低于TAVR,6和12个月时相似。
临床怎么用
- 中危主动脉狭窄患者选择TAVR或SAVR时,应权衡早期神经事件风险与远期卒中率。
- 术后早期需关注卒中及脑病对死亡率和生活质量的短期影响。
局限性
- 分析基于改良意向治疗人群,非全部随机人群。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neurological events after aortic valve interventions are associated with increased mortality and morbidity. Transcatheter aortic valve replacement (TAVR) is increasingly offered for lower-risk patients with severe aortic stenosis, previously considered candidates for surgical aortic valve replacement (SAVR). Differences in post-procedural neurological events have important implications in treatment allocation. OBJECTIVES: The authors sought to analyze the neurological events in the randomized SURTAVI (Surgical Replacement and Transcatheter Aortic Valve Implantation) trial. METHODS: Patients with severe, symptomatic aortic stenosis at intermediate surgical risk were randomized 1:1 to TAVR or SAVR. The rates of neurological events and quality of life were analyzed at 30 days, and 6 and 12 months post-procedure in a modified intention-to-treat population (mean age 79.8 ± 6.2 years; N = 1,660). RESULTS: The rates of early (30-day) stroke and post-procedural encephalopathy were higher after SAVR versus TAVR (5.4% vs. 3.3%; p = 0.031; and 7.8% vs. 1.6%; p < 0.001, respectively). At 12 months, the rate of stroke was not different between SAVR and TAVR (6.9% vs. 5.2%; p = 0.136). Early stroke and early encephalopathy resulted in an elevated mortality at 12 months in both treatment groups. Quality of life after an early stroke was significantly lower in SAVR versus TAVR patients at 30 days and was similar at 6 and 12 months. CONCLUSIONS: The early stroke rate was lower after TAVR than SAVR. In patients with early strokes, QOL improved earlier after TAVR. At 12-month follow-up, stroke rates and QOL were not different between TAVR and SAVR patients. (Surgical Replacement and Transcatheter Aortic Valve Implantation [SURTAVI]; NCT01586910).
引用
- Durko AP, Reardon MJ, Kleiman NS, et al. Neurological Complications After Transcatheter Versus Surgical Aortic Valve Replacement in Intermediate-Risk Patients. J Am Coll Cardiol. 2018. PMID: 30360820. doi:10.1016/j.jacc.2018.07.093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。